Combination pharmacotherapy for MASH: Potential synergistic approaches
This review discusses potential synergistic approaches for combination pharmacotherapy in metabolic dysfunction-associated steatotic liver disease (MASLD). The authors describe the spectrum of MASLD and the challenges in demonstrating efficacy of single agents in phase 3 trials. The review highlights the recent conditional approval of monotherapies targeting metabolic pathways, such as resmetirom and semaglutide, and discusses the rationale for combining these agents.
What to check after reading
This is a review discussing combination strategies for MASH, noting the challenge of demonstrating efficacy for single agents in phase 3 trials.
Source
Calendar dates show when a case was added or scheduled. For event dates, check the original source.